Department of Otorhinolaryngology - Head and Neck Surgery, Perelman School of Medicine at the University of Pennsylvania, 421 Curie Blvd, BRB 1220, Philadelphia, PA 19104, USA.
Department of Otorhinolaryngology - Head and Neck Surgery, Perelman School of Medicine at the University of Pennsylvania, 421 Curie Blvd, BRB 1220, Philadelphia, PA 19104, USA; Department of Pathology, UT Health Science Center, 6431 Fannin St., MSB 2.262, Houston, TX 77030, USA.
J Control Release. 2018 Jun 10;279:243-250. doi: 10.1016/j.jconrel.2018.04.028. Epub 2018 Apr 16.
Hearing loss is the most prevalent sensory disability worldwide and may be caused by age, drugs or exposure to excessive noise. We have previously developed a minimally-invasive nanohydrogel drug delivery system that successfully delivers nanoparticles into the inner ear. We have substantially extended this technique by functionalizing the nanoparticles and introducing a targeting peptide which recognizes prestin, a transmembrane electromotile protein uniquely expressed in outer hair cells (OHCs) of the inner ear. We demonstrate the successful delivery of molecules and plasmids specifically to OHCs. When compared to untargeted nanoparticles, the delivery of a c-Jun N-terminal kinase (JNK) inhibitor, D-JNKi-1, to OHCs by targeted nanoparticles improved protection from noise induced hearing loss (NIHL). This is the first demonstration of a protection from NIHL using a novel safe and controllable delivery system which is minimally-invasive to the inner ear and, as such, is an extremely appealing technique for use in many clinical applications.
听力损失是全球最普遍的感觉性残疾,可能由年龄、药物或暴露于过度噪音引起。我们之前开发了一种微创纳米水凝胶药物输送系统,该系统可成功将纳米颗粒递送至内耳。我们通过对纳米颗粒进行功能化并引入靶向肽来大大扩展了这项技术,该靶向肽可识别 prestin,一种在外毛细胞(OHC)中特异表达的跨膜电动蛋白。我们证明了分子和质粒可特异性递送至 OHC。与非靶向纳米颗粒相比,通过靶向纳米颗粒将 c-Jun N 末端激酶(JNK)抑制剂 D-JNKi-1 递送至 OHC 可改善对噪声诱导听力损失(NIHL)的保护。这是首次使用新型安全可控的递药系统来防止 NIHL 的证明,该系统对内耳的微创性,因此是一种极具吸引力的技术,可用于许多临床应用。